LONDON, UK and BOSTON, MA - September 18, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alltrna and is pleased to announce the placement of David (Dave) Hava, Ph.D., as Chief Scientific Officer (CSO).

Alltrna, a Flagship Pioneering company, is unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease.

Victoria House, a newly restored Grade II listed building in London’s Bloomsbury Square, officially opened its doors yesterday (16 September) as a state-of-the-art life sciences hub.

Cambridge, UK – 17 September 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.
This international trial has recruited 41 patients at clinical centres in the UK, France, Italy, and Spain. Initial results are expected in the first half of 2026.

A new research report, commissioned by Pioneer Group and The Crown Estate, has found that investing £15bn in UK university spinouts over the next 10 years could leverage a further £27bn of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, and boosting UK science on the global stage.

Authored by Henham Strategy, the report, titled: ‘Bridging the Capital Gap for UK Research Commercialisation,’ outlines the investment needed to translate the UK’s scientific excellence into global impact.

LONDON, UK, and MILAN, Italy, September 16, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, is proud of the successful placement of Valerio Ferri as Chief Executive Officer (CEO) at ExoLab Italia.

ExoLab Italia is a biotech company producing plant-based exosomes for the cosmetics, nutraceutical, and pharmaceutical markets.

Amsbio offers a wide selection of over 325,000 pre-characterized chemical compounds to support your drug screening applications for discovery and development.

From individual inhibitors, agonists and natural products to ready-to-screen compound libraries, these cost-effective, high-quality reagents are perfect for both academic and industrial research.

The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.

Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals.

Sandwich, UK and Illkirch-Graffenstaden, France (10 September 2025) – Logical Biological, biospecimen and critical raw material leader based at Discovery Park, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic international partnership to deliver engineered disease state materials for diagnostic and research markets.